| Literature DB >> 30799307 |
Jinglu Zhao1, Yun Zhu1, Xiaoli Xie1, Yuxiao Yao1, Jiao Zhang2, Ruizhong Zhang1, Lihua Huang1, Jiwen Cheng3, Huimin Xia1, Jing He1, Yan Zhang1.
Abstract
Hirschsprung disease (HSCR) is a heterogeneous congenital disorder that affects the enteric nervous system, while neuroblastoma is an embryonal tumor of the sympathetic nervous system. Familial cases of both HSCR and neuroblastoma appear to be functionally linked to PHOX2B, which plays a key role in the development of neural crest derivatives. However, the association between common PHOX2B variants and disease risk is contested. Additionally, large-scale examination for pleiotropy or shared genetic susceptibility in sporadic HSCR and neuroblastoma cases lacks theoretical support. Here, we report the first examination of PHOX2B in 1470 HSCR and 469 neuroblastoma patients with matched healthy controls. The PHOX2B rs28647582 polymorphism was found to be associated with HSCR (P = 2.21E-03, OR = 1.26), and each subtype of the ailment (3.22E-03 ≤ P ≤ 0.43, 1.11 ≤ OR ≤ 2.32). The association between rs28647582 and NB risk was consistent with HSCR in a recessive model, though the P value was marginal (P = 0.06). These new genetic findings indicate the potential pleiotropic effects of PHOX2B in both HSCR and neuroblastoma, which could guide the development of therapeutic targets for the treatment of related neurodevelopmental disorders.Entities:
Keywords: Hirschsprung’s disease; PHOX2B; neuroblastoma; pleiotropic effect
Year: 2019 PMID: 30799307 PMCID: PMC6402522 DOI: 10.18632/aging.101834
Source DB: PubMed Journal: Aging (Albany NY) ISSN: 1945-4589 Impact factor: 5.682
Replication results of PHOX2B SNP (rs28647582) in a South Chinese population using 1470 cases and 1473 controls.
| SNP | Gene | CHR | BP | A1/A2 | F_A | F_U | P | OR | 0.95 CI |
| rs28647582 | 4 | 41747248 | T/C | 0.87 | 0.84 | 1.26 | (1.09~1.45) |
SNP, single Nucleotide Polymorphism; CHR, chromosome; BP, base pair where the SNP is located; A1/A2, risk allele and protective allele to disease; F_A/F_U, risk allele frequency of the SNP in cases or controls; OR, odds ratio; CI, confidence interval. The P value indicates the significance based on allelic association tests. Calculation of the OR was also based on the risk allele of each SNP.
Detailed replication results with different genetic models.
| SNP | A1/A2 | TEST | AFF | UNAFF | DF | P | OR | 0.95 CI |
| rs28647582 | ||||||||
| T/C | Genotypic | 1080/346/21 | 1028/374/49 | 2 | / | / | ||
| T/C | Additive | 2506/388 | 2430/472 | 1 | 1.26 | (1.09~1.45) | ||
| T/C | Dominant | 1426/21 | 1402/49 | 1 | 2.37 | (1.42~3.98) | ||
| T/C | Recessive | 1080/367 | 1028/423 | 1 | 1.21 | (1.03~1.43) |
HWE, Hardy-Weinberg equilibrium; A1/A2, risk allele and protective allele to disease; AFF/UNAFF, cases and controls; DF, degree of freedom; OR, odds ratio; CI, confidence interval. The P value indicates the significance based on allelic association tests. Calculation of OR was also based on the risk allele of each SNP.
The association results of PHOX2B gene SNP (rs28647582) to different subclinical features classified by aganglionosis length.
| CHR | SNP | Length of aganglionic segment | A1/A2 | F_A | F_U | P | OR |
| 4 | rs28647582 | S-HSCR | T/C | 0.86 | 0.84 | 1.22(1.04~1.43) | |
| L-HSCR | 0.85 | 0.84 | 1.11(0.86~1.42) | ||||
| TCA | 0.92 | 0.84 | 2.32(1.30~4.11) |
SNP, single nucleotide polymorphism; CHR, chromosome; S-HSCR, short-segment HSCR; L-HSCR, long-segment HSCR; TCA, total colonic aganglionosis; A1/A2, risk allele and protective allele to disease; F_A/F_U, risk allele frequency of the SNP in cases or controls; OR, odds ratio; CI, confidence interval. The P value indicates the significance based on allelic association tests. Calculation of OR was also based on the risk allele of each SNP.
Association of PHOX2B rs28647582T>C polymorphism with neuroblastoma risk.
| Genotype | Cases | Controls | P a | Crude OR | P | Adjusted OR | P b |
| rs28647582 (HWE=0.538) | |||||||
| TT | 320 (68.23) | 662 (66.33) | 1.00 | 1.00 | |||
| TC | 140 (29.85) | 298 (29.86) | 0.97 (0.76-1.24) | 0.817 | 0.97 (0.76-1.23) | 0.794 | |
| CC | 9 (1.92) | 38 (3.81) | 0.49 (0.23-1.03) | 0.058 | 0.49 (0.23-1.02) | 0.058 | |
| Additive | 0.155 | 0.88 (0.72-1.08) | 0.214 | 0.88 (0.71-1.08) | 0.204 | ||
| Dominant | 149 (31.77) | 336 (33.67) | 0.471 | 0.92 (0.73-1.16) | 0.471 | 0.91 (0.72-1.16) | 0.454 |
| Recessive | 460 (98.08) | 960 (96.19) | 0.055 | 0.49 (0.24-1.03) | 0.060 | 0.49 (0.24-1.03) | 0.060 |
OR, odds ratio; CI, confidence interval; HWE, Hardy-Weinberg equilibrium.
a χ2 test for genotype distributions between neuroblastoma patients and controls.
b Adjusted for age and gender.
Stratification analysis of the association between PHOX2B rs28647582 T>C polymorphism and neuroblastoma risk.
| Variables | Rs28647582 | Crude OR | P | Adjusted OR a | P a | |
| TT/TC | CC | (95% CI) | (95% CI) | |||
| Age, month | ||||||
| ≤18 | 165/378 | 4/12 | 0.76 (0.24-2.40) | 0.645 | 0.79 (0.25-2.49) | 0.685 |
| >18 | 295/582 | 5/26 | 0.38 (0.14-1.00) | 0.050 | 0.38 (0.15-1.00) | 0.051 |
| Gender | ||||||
| Females | 192/397 | 4/17 | 0.49 (0.16-1.47) | 0.200 | 0.49 (0.16-1.47) | 0.202 |
| Males | 268/563 | 5/21 | 0.50 (0.19-1.34) | 0.169 | 0.49 (0.18-1.33) | 0.162 |
| Sites of origin | ||||||
| Adrenal gland | 157/960 | 5/38 | 0.81 (0.31-2.08) | 0.653 | 0.80 (0.31-2.06) | 0.641 |
| Retroperitoneal | 135/960 | 3/38 | 0.56 (0.17-1.84) | 0.341 | 0.56 (0.17-1.85) | 0.342 |
| Mediastinum | 120/960 | 1/38 | 0.21 (0.03-1.55) | 0.126 | 0.21 (0.03-1.52) | 0.122 |
| Others | 40/960 | 0/38 | / | / | / | / |
| Clinical stages | ||||||
| I+II+4s | 229/960 | 4/38 | 0.44 (0.16-1.25) | 0.123 | 0.44 (0.15-1.24) | 0.119 |
| III+IV | 211/960 | 5/38 | 0.60 (0.23-1.54) | 0.287 | 0.60 (0.23-1.53) | 0.283 |
OR, odds ratio; CI, confidence interval.
aAdjusted for age and gender, omitting the corresponding stratification factor.